Valensa International Awarded US Patent For EyePro MD

94439fc9-945c-4257-8ac5-66bb91402695articleimage.jpg

07 Jun 2017 --- Florida-based Valensa International has announced that it has received a US patent for its EyePro MD formula, which claims eye healthcare benefits related to its super-blend of lutein, zeaxanthin and astaxanthin mixed with omega 3 essential oils from krill, algae or perilla seed. The EyePro MD patented formulas feature the process of purifying the all-natural ingredients through extraction and stabilization using Valensa’s proprietary O2B peroxidation blocker technology and its Supercritical CO2 extraction technology.

Valensa International’s commercial formula includes a potent carotenoid portfolio, phospholipids and high ALA plant-derived omega 3 oils purified through Supercritical CO2 technology (also available with added krill or algae-based oils).

According to the company, the patent, titled “Eye Health Composition and Method using Plant-Derived Seed Extract Rich in Essential Fatty Acids Derived from Perilla Seed and Carotenoids,” outlines the health benefits this combination of all-natural, ingredients provides in EyePro MD. The formula delivers macular carotenoid supplementation, phospholipids for enhanced bioavailability and omega 3 essential fatty acids known to support heart and cognitive functions. Although the benefits of krill oil and algae oils are noteworthy, perilla seed oil offers a unique 6:1 ratio of ALA to LA or nearly twice the ratio found in flax seed oil.

“We have designed a small soft gel loaded with a potent combination of ingredients that can be absorbed efficiently to optimize eye health,” says Dr. John Minatelli, Senior Vice President of Business Development at Valensa. “Now with the patent IP in place, distributors and manufactures from the food and nutraceutical industry can include EyePro MD in their products knowing there’s nothing else like it on the market.” 

EyePro MD provides a potent array of carotenoids, which supports numerous eye health functions, according to the two-year, randomized study “The Carotenoid in Age-Related Maculopathy Italian Clinical Study” (CARMIS) in 2011. The carotenoid combination in EyePro MD was shown to reduce eye fatigue (Asthenopia) and contrast sensitivity. 

EyePro MD’s carotenoid portfolio is backed by additional science, including AREDS2, TOZAL and LAST studies as well as research conducted in Japan on astaxanthin for the treatment of eye fatigue, accommodation and protection from blue light damage.

The Japanese studies further confirmed that astaxanthin alone improved eye fatigue caused by blue light-induced oxidative stress (Digital Eye) in humans.  According to Dr. Minatelli, these studies also confirmed that astaxanthin is quickly incorporated into the eye’s vitreous humor where it acts as a potent blue light filter to protect the macular pigment degradation on the rod and cone surfaces. This allows the carotenoid portfolio to reduce oxidative stress to the associated retinal and macular cells thus protecting and supporting eye health. 

Stabilized Perilla seed oil reduces ocular inflammation by providing supplementation of ALA-based omega 3, an important pre-metabolite of EPA and DHA which are membrane-bound precursors of the potent anti-inflammatory prostaglandins. Seed oils rich in omega 3 content also support heart and cognitive health support.

According to the company, EyePro MD features a “powerful carotenoid combination and omega 3/phospholipid delivery system,” adding that it has a “zinc-free formula and is non-GMO, organic, no allergens, 100% vegetarian.”

Related Articles

Nutrition & Health News

EID Parry and Synthite Industries partner on phycocyanin production 

08 Feb 2018 --- Enhanced health company Valensa International has entered into a joint venture agreement between Valensa’s parent company EID Parry and Synthite Industries Ltd, which promises to boost microalgae extracts for nutraceutical applications. It involves a US$6.5 million investment in an India-based manufacturing facility for the extraction of Parry Organic Spirulina to produce Phycocyanin, which Valensa will be developing for dietary supplements, functional and medical foods.

Nutrition & Health News

The US Council for Responsible Nutrition welcomes eight new companies as members

30 Jan 2018 --- The Council for Responsible Nutrition (CRN), a US trade association for the dietary supplement and functional food industry, has welcomed eight new companies to its membership ranks.

Nutrition & Health News

Omega 3s from fish trump flax for cancer prevention, study finds

29 Jan 2018 --- Omega 3s from fish pack a stronger punch than flaxseed and other oils when it comes to cancer prevention, according to a study conducted at the University of Guelph. Marine-based omega 3s are eight times more effective at inhibiting tumor development and growth, says lead scientist Professor David Ma.

Nutrition & Health News

Non-GMO astaxanthin: Algalif achieves verification

24 Jan 2018 --- Algalif, an Icelandic producer of pure, high-grade, natural astaxanthin from microalgae, has achieved Non-GMO Project verification for its Astalíf 5% and 10% oleoresin ingredients.

Business News

Frutarom takes full ownership of Enzymotec, sells krill oil business to Aker BioMarine

19 Jan 2018 --- Frutarom Industries has completed its acquisition of full ownership of Enzymotec. Upon completion of the transaction on January 11, 2018, Enzymotec shares were delisted from trading on NASDAQ and it ceased to be a public company. Frutarom reports that it is working towards implementing the full merger plan of all Enzymotec activities through the rapid, efficient and comprehensive integration of both companies’ activities in the areas of management, R&D, sales and marketing, production and supply chain. As part of its merger plan, Frutarom has announced the sale of Enzymotec’s krill oil business to Aker BioMarine.

More Articles
URL : http://www.nutritioninsight.com:80/news/valensa-international-awarded-us-patent-for-eyepro-md.html